Uraemic toxins and cardiovascular disease: In vitro research versus clinical outcome studies

NDT Plus

Volumn 1, Issue 1, 2008, Pages 2-10

  Vanholder, Raymond ^a   Van Laecke, Steven ^a   Verbeke, Francis ^a   Glorieux, Griet ^a   Van Biesen, Wim ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Cardiovascular disease; Clinical outcome studies; In vitro; Uraemic toxins

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED OXIDATION PROTEIN PRODUCT; ALPHA AMINO ACID; ANGIOTENSIN A; BETA 2 MICROGLOBULIN; CYTOKINE; DINUCLEOTIDE POLYPHOSPHATE; GUANIDINE DERIVATIVE; HOMOCYSTEINE; INDOLE DERIVATIVE; N(G),N(G) DIMETHYLARGININE; PARA CRESYLSULFATE; PHENOL DERIVATIVE; PHENYLACETIC ACID; PHOSPHATE; RESISTIN; SYMMETRIC DIMETHYLARGININE; TOXIN; UNCLASSIFIED DRUG; UREMIC TOXIN;

ALBUMINURIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; HEMODIALYSIS; HUMAN; HYPOALBUMINEMIA; IN VITRO STUDY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SOLUTE; TOXICITY TESTING; UREMIA;

EID: 39749142148     PISSN: 17530784     EISSN: 17530792     Source Type: Journal    
DOI: 10.1093/ndtplus/sfm024     Document Type: Review

References (73)